Reina Haque to Breast Neoplasms
This is a "connection" page, showing publications Reina Haque has written about Breast Neoplasms.
Connection Strength
6.030
-
Comorbidity burden and risk of second primary non-breast cancer in breast cancer survivors. Cancer Epidemiol. 2025 Aug; 97:102867.
Score: 0.549
-
Persistent prescription opioid use and all-cause mortality following the first-year breast cancer survivorship. JNCI Cancer Spectr. 2025 Apr 30; 9(3).
Score: 0.544
-
Association of Physical Activity With Risk of Mortality Among Breast Cancer Survivors. JAMA Netw Open. 2022 11 01; 5(11):e2242660.
Score: 0.458
-
Sleep medication use and risk of fractures in breast cancer survivors. Breast Cancer Res Treat. 2021 Dec; 190(3):541-548.
Score: 0.424
-
SARS-CoV-2 Testing, Positivity Rates, and Healthcare Outcomes in a Cohort of 22,481 Breast Cancer Survivors. JCO Clin Cancer Inform. 2021 02; 5:168-175.
Score: 0.405
-
Cardiovascular Disease After Aromatase Inhibitor Use. JAMA Oncol. 2016 Dec 01; 2(12):1590-1597.
Score: 0.304
-
Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
Score: 0.289
-
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
Score: 0.283
-
A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. Med Care. 2015 Apr; 53(4):380-5.
Score: 0.270
-
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015 Jul 01; 121(13):2147-55.
Score: 0.269
-
Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila). 2014 Apr; 7(4):378-87.
Score: 0.249
-
Comorbidities and cardiovascular disease risk in older breast cancer survivors. Am J Manag Care. 2014; 20(1):86-92.
Score: 0.248
-
Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med. 2012 Dec; 1(3):318-27.
Score: 0.227
-
Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21(10):1848-55.
Score: 0.227
-
Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomarkers Prev. 2011 Oct; 20(10):2120-6.
Score: 0.211
-
Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett. 2005 Apr 18; 221(1):61-5.
Score: 0.136
-
Accelerated mononuclear cell telomere attrition in breast cancer survivors with depression history: A 2-year longitudinal cohort study. Cancer. 2022 Aug 15; 128(16):3109-3119.
Score: 0.111
-
Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample. Breast Cancer Res Treat. 2017 01; 161(2):375-384.
Score: 0.076
-
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat. 2015 Dec; 154(3):609-16.
Score: 0.071
-
Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
Score: 0.069
-
Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. Breast Cancer Res Treat. 2014 Jul; 146(2):401-9.
Score: 0.064
-
Fracture risk in older, long-term survivors of early-stage breast cancer. J Am Geriatr Soc. 2013 Jun; 61(6):888-95.
Score: 0.059
-
Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013 Jun; 139(2):453-60.
Score: 0.059
-
Validation of AJCC TNM staging for breast tumors diagnosed before 2004 in cancer registries. Cancer Causes Control. 2012 Sep; 23(9):1587-91.
Score: 0.056
-
Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
Score: 0.055
-
Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec; 33(12):1802-8.
Score: 0.047
-
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
Score: 0.047
-
Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):2979-83.
Score: 0.046
-
Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery. J Clin Oncol. 2009 Jul 01; 27(19):3211-6.
Score: 0.045
-
Abstracting height and weight from medical records, and breast cancer pathologic factors. Cancer Causes Control. 2008 Dec; 19(10):1217-26.
Score: 0.042
-
Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol. 2007 Nov; 20(11):1149-55.
Score: 0.040
-
Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008 Feb; 107(3):397-403.
Score: 0.039
-
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010 Jan; 63(1):64-74.
Score: 0.011